查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2010931

肝癌治疗市场：2026-2032年全球市场预测（依治疗方法、癌症类型、给药途径、药物类别、最终用户和分销管道划分）

Liver Cancer Drugs Market by Therapy Type, Cancer Type, Administration Route, Drug Class, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年肝癌治疗市场价值 41 亿美元，预计到 2026 年将成长至 46.7 亿美元，复合年增长率为 14.95%，到 2032 年将达到 108.8 亿美元。

主要市场统计数据
基准年 2025 41亿美元
预计年份：2026年 46.7亿美元
预测年份 2032 108.8亿美元
复合年增长率 (%) 14.95%

肝臟肿瘤学领域的典范转移，是由免疫肿瘤学、精准医学和复杂的管理挑战的整合所驱动的。

肝癌治疗正处于转折点，其特点是科学的快速进步、临床范式的转变以及商业性趋势的变化。近年来，免疫肿瘤学方法已稳步融入现有的标靶治疗治疗和细胞毒性疗法中，推动了将全身性治疗与局部和区域干预相结合的多学科治疗路径的形成。因此，临床医生、保险公司和製药公司正在重新思考治疗流程，以期在克服医疗资源获取障碍和复杂的报销环境的同时，优化治疗效果。

免疫肿瘤学、精准诊断和新的给药模式的突破如何重新定义肝癌的治疗和给药方式。

肝癌治疗格局已发生翻天覆地的变化，这主要得益于免疫疗法、标靶小分子药物和联合治疗策略的突破性进展。查核点抑制剂与抗血管新生药物的联合应用彻底革新了一线治疗方案，而针对特定分子异常的标靶抑制剂则为以往治疗不足的患者群体提供了更多选择。同时，诊断准确性的提高，包括分子谱分析的广泛应用，使得患者与治疗方法的匹配更加精准，加速了向个人化医疗的转变。

评估 2025 年关税变化将如何加剧供应链脆弱性、影响价格结构并加速以本地为中心的製造策略。

计划于2025年实施的关税征收和贸易政策调整，正对肝癌治疗生态系统产生累积影响，暴露出全球药品供应链和采购惯例中原有的脆弱性。活性成分、辅料和成品进口关税的提高，可能会增加生产商和经销商的接收成本，促使他们重新评估筹资策略并调整商业定价模式。因此，医疗服务提供者和保险公司将面临价格压力，这可能会影响药物选择和患者用药计划。

透过全面的細項分析，阐明治疗方法、癌症亚型、给药途径和通路如何影响治疗的采用。

细分市场分析透过将市场划分为治疗方法类型、癌症亚型、给药途径、药物类别、最终用户和分销管道等框架，为理解肝癌治疗的需求和供应提供了精准的观点。依治疗方法类型（例如化疗、免疫疗法、放射线治疗和标靶治疗疗法）进行分类，可以清楚观察每个治疗阶段的临床结果和资源消耗。同样，按癌症类型（例如胆管癌、肝母细胞瘤和肝细胞癌）进行细分，可以揭示未满足需求的差异、基于年龄和生物学特征的治疗选择，以及利基创新机会。

影响美洲、欧洲、中东和非洲以及亚太地区治疗方法引进和提供的地区差异和促进因素。

区域趋势对治疗方法的可近性、监管管道和商业策略有显着影响，美洲、欧洲、中东和非洲以及亚太地区之间存在着明显的差异。在美洲，先进的肿瘤学基础设施、广泛的临床试验网络和完善的医保报销机制使得新型系统性疗法能够相对快速地引入市场。另一方面，支付方的审查和成本效益评估正日益影响治疗方法的生命週期管理。专科医疗中心的地理集中也有利于复杂病例的重症监护，但在资源匮乏的地区，医疗资源的可近性仍存在差距。

企业策略趋势表明，研发合作、投资组合多元化和真实世界数据策略正在塑造竞争地位。

肝癌治疗领域的关键趋势表明，策略性研发投资、合作以及生命週期管理相结合，旨在实现长期成长并保持临床意义。製药和生物技术公司越来越重视利用互补作用机制的联合治疗，同时投资于伴随诊断，以优化患者筛选并向支付方证明其价值。大型跨国公司与专业生技公司之间的策略合作十分普遍，这有助于加快新药上市速度并分担研发风险。

为产业领导者提供可操作的策略指南，以加强供应链韧性、精准诊断和以价值为中心的商业化方法。

产业领导者必须采取一系列切实可行的措施，以应对肝癌治疗领域快速变化的局面，确保患者能够持续获得治疗，并实现商业性的永续发展。首先，他们应优先考虑供应链多元化和策略性供应商选择，以减少对单一供应商的依赖，并最大限度地降低贸易政策波动和原材料短缺的风险。投资区域製造能力和灵活的生产平台，可以提高韧性，同时加快关键疗法的上市速度。

调查方法，结合专家进行的初步研究和严格的二次研究，以检验临床、监管和商业性的发现。

本研究采用混合方法，将专家的初步意见与全面的二次分析相结合，从而对肝癌治疗提供了可靠且令人信服的观点。初步研究包括对临床意见领袖、肿瘤药剂师、保险公司代表和高级商业管理人员进行结构化访谈和讨论，以了解真实的临床实践模式、报销趋势和策略重点。这些专家见解用于阐述文献分析中涌现的趋势和检验。

强调需要将科学创新、营运韧性和以支付方为中心的证据结合起来，最终实现整合，将治疗方面的进步与患者的益处联繫起来。

总之，肝癌治疗正受到多种因素的共同影响而重塑，包括免疫肿瘤学和标靶治疗的科学创新、不断改进的给药和治疗方式，以及贸易政策和区域医疗资源分配不均等外部压力。这些因素在为改善患者预后创造新机会的同时，也带来了营运和报销方面的复杂性，需要产业、医疗服务提供者和支付方协调应对。最终，这将形成一个更动态、以患者为中心的环境，在这个环境中，精准性、柔软性和实证商业化都备受重视。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 肝癌治疗市场（依治疗方法划分）

  • 化疗
  • 免疫疗法
  • 放射线治疗
  • 分子标靶治疗

第九章 依癌症类型分類的肝癌治疗市场

  • 胆管癌
  • 肝母细胞瘤
  • 肝细胞癌（HCC）

第十章：依给药途径分類的肝癌治疗市场

  • 静脉
  • 口服
  • 皮下注射

第十一章 肝癌治疗市场：依药物类别划分

  • 细胞毒性药物
  • 单株抗体
  • 蛋白酪氨酸激酶抑制剂（TKIs）

第十二章 肝癌治疗药物市场：依最终用户划分

  • 居家医疗
  • 医院
  • 专科诊所

第十三章 肝癌治疗药物市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十四章 肝癌治疗药物市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 肝癌治疗药物市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 肝癌治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国肝癌治疗市场

第十八章：中国肝癌治疗药物市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Agenus Inc.
  • AstraZeneca AB
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Bristol-Myers Squibb Company
  • Can-Fite BioPharma Ltd.
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  • CStone Pharmaceuticals
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • Hoffmann-La Roche Inc.
  • Innovent Biologics, Inc.
  • Ipsen SA
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Roche Holding AG（F. Hoffmann-La Roche Ltd）
  • Zai Lab Limited
Product Code: MRR-434CCDA05287

The Liver Cancer Drugs Market was valued at USD 4.10 billion in 2025 and is projected to grow to USD 4.67 billion in 2026, with a CAGR of 14.95%, reaching USD 10.88 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.10 billion
Estimated Year [2026] USD 4.67 billion
Forecast Year [2032] USD 10.88 billion
CAGR (%) 14.95%

An evolving therapeutic paradigm in liver oncology driven by immuno-oncology integration, precision medicine, and complex delivery challenges

Liver cancer therapeutics are at an inflection point, characterized by rapid scientific advances, shifting clinical paradigms, and evolving commercial dynamics. Recent years have seen the steady integration of immuno-oncology approaches alongside established targeted therapies and cytotoxic regimens, prompting multidisciplinary care pathways that blend systemic treatments with locoregional interventions. As a result, clinicians, payers, and manufacturers are re-evaluating treatment algorithms to optimize outcomes while navigating access barriers and complex reimbursement environments.

Transitioning from historical monotherapy models to combination regimens has created new opportunities and new complexities for clinical development, regulatory approval, and market deployment. Patient stratification through molecular profiling and the growing importance of real-world evidence are reshaping trial design and post-approval evidence generation. Consequently, strategic stakeholders must balance innovation with pragmatic considerations such as supply chain resilience, pricing strategies, and stakeholder education to ensure that therapeutic advances translate into measurable patient benefit.

Ultimately, the modern landscape demands an integrated perspective that accounts for evolving science, multi-stakeholder incentives, and the operational realities of delivering care across diverse settings. This introduction sets the stage for a deeper exploration of the disruptive shifts, policy influences, segmentation nuances, geographic differentials, competitive maneuvers, and recommended actions that follow in this executive summary.

How immuno-oncology breakthroughs, precision diagnostics, and novel administration models are collectively redefining liver cancer treatment and care delivery

The liver cancer treatment landscape has undergone transformative shifts driven by breakthroughs in immunotherapy, targeted small molecules, and combination strategies. Checkpoint inhibition paired with antiangiogenic agents has altered frontline care pathways, while targeted inhibitors for specific molecular aberrations have expanded options for previously underserved subpopulations. Concurrently, improvements in diagnostic precision, including more widespread molecular profiling, have made it possible to match patients to therapies with greater accuracy, accelerating the move toward personalized regimens.

As clinical benefits have been demonstrated in both survival and tolerability for select combinations, payer and provider systems are recalibrating care pathways to incorporate these innovations. This recalibration has prompted new collaborations between oncology centers, diagnostic laboratories, and specialty pharmacies to deliver integrated care. Moreover, the growth of oral targeted therapies and subcutaneous formulations is changing administration dynamics, enabling more outpatient and home-based care models that reduce hospital burden and improve patient convenience.

In parallel, regulatory frameworks are evolving to accommodate adaptive trial designs and accelerated approval pathways, which has encouraged sponsors to pursue novel endpoints and surrogate markers. As a result, the therapeutic trajectory is defined not only by scientific advances but by systemic shifts in care delivery, regulatory interaction, and commercial execution that together are redefining what constitutes best-in-class treatment for liver malignancies.

Assessment of how 2025 tariff shifts are compounding supply chain fragility, influencing pricing structures, and accelerating localized manufacturing strategies

The introduction of tariffs and trade policy shifts in 2025 has had a cumulative impact on the liver cancer therapeutic ecosystem by accentuating pre-existing vulnerabilities in global pharmaceutical supply chains and procurement practices. Increased import duties on active pharmaceutical ingredients, excipients, and finished formulations can raise landed costs for manufacturers and distributors, prompting reassessment of sourcing strategies and potential adjustments to commercial pricing models. In turn, healthcare providers and payers may face pricing pressures that influence formulary decisions and patient access programs.

Moreover, tariffs can accelerate efforts to regionalize manufacturing and strengthen local supply resilience, prompting investment in geographically diversified production capacity and strategic stockpiling. While reshoring and nearshoring efforts can mitigate future disruption risk, they also introduce short-term capital expenditures and regulatory complexities associated with establishing compliant manufacturing sites. Consequently, market entrants and incumbents must weigh the trade-offs between cost, agility, and compliance in planning their manufacturing footprints.

Furthermore, trade policy volatility may affect the cadence of clinical trial supplies and the availability of specialized assays required for patient selection, with potential downstream impacts on enrollment and study timelines. For stakeholders operating across multiple jurisdictions, tariffs add a layer of strategic uncertainty that underscores the importance of flexible contracting, robust supplier qualification, and proactive engagement with payers to preserve patient access amidst shifting cost structures.

Comprehensive segmentation insights revealing how therapy modalities, cancer subtypes, administration routes, and distribution pathways shape treatment adoption

Segmentation analyses provide a nuanced lens to understand therapeutic demand and delivery in liver cancer by framing the market across therapy type, cancer subtype, administration route, drug class, end user, and distribution channel. When treatments are categorized by therapy type such as chemotherapy, immunotherapy, radiation therapy, and targeted therapy, one can observe distinct clinical trajectories and resource implications across lines of care. Similarly, segmenting by cancer type-covering cholangiocarcinoma, hepatoblastoma, and hepatocellular carcinoma-illuminates differential unmet needs, age- and biology-driven treatment choices, and opportunities for niche innovation.

Administration route segmentation, which includes intravenous, oral, and subcutaneous options, reveals how delivery modality affects patient adherence, outpatient utilization, and the economics of care. Examination by drug class differentiates cytotoxic agents from monoclonal antibodies and tyrosine kinase inhibitors, each bringing a unique safety, monitoring, and development profile that shapes clinical adoption. End user segmentation across home care, hospitals, and specialty clinics highlights the operational pathways through which therapies are delivered and the corresponding requirements for patient education and monitoring.

Finally, distribution channel analysis, spanning hospital pharmacy, online pharmacy, and retail pharmacy, sheds light on access pathways, fulfillment complexity, and the evolving role of digital and specialty dispensing models. Taken together, these segmentation perspectives enable stakeholders to identify targeted commercialization strategies, prioritize evidence generation in subpopulations, and design delivery models that align with clinical practice and patient preferences.

Regional differentiators and access enablers across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence therapeutic adoption and delivery

Regional dynamics exert a strong influence on therapy availability, regulatory pathways, and commercial strategies, with clear distinctions across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, advanced oncology infrastructures, broad clinical trial networks, and progressive reimbursement frameworks have enabled relatively rapid adoption of novel systemic regimens, while payer scrutiny and cost-effectiveness evaluations increasingly shape lifecycle management of therapies. Geographic concentration of specialty centers also facilitates centralized care for complex cases, but disparities in access persist in under-resourced areas.

Within Europe, Middle East & Africa, heterogeneous regulatory regimes and variable healthcare financing models produce a patchwork of access and uptake. High-income European markets often see quicker alignment with guideline recommendations and broader reimbursement pathways, whereas regions with constrained resources must balance high-cost innovations against competing health priorities, driving interest in tiered pricing and access programs. The Middle East and parts of Africa face distinct infrastructure and diagnostic capacity challenges that require tailored implementation approaches.

Asia-Pacific exhibits a spectrum from advanced market adoption, driven by large public health systems and active domestic manufacturing, to emerging markets where diagnostic capacity and distribution logistics are still expanding. Regulatory modernization efforts and local clinical development partnerships are notable trends in the region, supporting both global clinical programs and regionally specific therapeutic innovations. Across all regions, cross-border collaboration, technology-enabled care models, and adaptive reimbursement mechanisms are emerging as critical enablers of broader patient access.

Strategic corporate patterns showing how R&D alliances, portfolio diversification, and real-world evidence strategies are shaping competitive positioning

Key corporate behaviors in the liver cancer therapeutics arena reveal a mix of strategic R&D investment, partnering activity, and lifecycle management aimed at sustaining long-term growth and clinical relevance. Pharmaceutical and biotechnology companies are increasingly prioritizing combination regimens that leverage complementary mechanisms of action, while also investing in companion diagnostics to improve patient selection and demonstrate value to payers. Strategic alliances between large multinationals and specialist biotech firms are commonplace, enabling speed-to-market for novel agents and the sharing of development risk.

Pipeline diversification is a central theme, with firms balancing small-molecule kinase inhibitors and cytotoxic programs alongside biologics, antibody-drug conjugates, and immune-modulating platforms. Companies are also focused on developing formulations and administration routes that support outpatient care, including oral and subcutaneous options that align with shifting provider preferences. From a commercial perspective, leaders are expanding patient support services and value-based arrangements to mitigate access hurdles and strengthen payer relationships.

Mergers and acquisitions, as well as selective licensing deals, remain important tools for accelerating access to promising assets and augmenting therapeutic portfolios. In parallel, firms are placing greater emphasis on real-world evidence generation and post-marketing surveillance to refine positioning, manage safety considerations, and inform iterative regulatory submissions. Collectively, these corporate strategies underscore a pragmatic convergence of scientific ambition and commercial discipline.

Actionable strategic directives for industry leaders to strengthen supply resilience, precision diagnostics, and value-focused commercialization approaches

Industry leaders must adopt a set of pragmatic, actionable measures to navigate the rapidly evolving liver cancer therapeutics landscape and to ensure sustainable patient access and commercial viability. First, supply chain diversification and strategic supplier qualification should be prioritized to reduce dependency on single-source suppliers and to minimize the disruption risk posed by trade policy fluctuations or raw material constraints. Investments in regional manufacturing capacity and flexible production platforms can both improve resilience and shorten time-to-market for critical therapies.

Second, stakeholders should invest in robust molecular diagnostic capabilities and companion diagnostic partnerships to enable precise patient selection, which enhances clinical outcomes and strengthens reimbursement cases. Third, value-based contracting and outcomes-based pricing models should be pursued in collaboration with payers and providers to align payment with real-world performance, thereby mitigating pricing pressure while facilitating access. Fourth, cross-sector collaborations that integrate digital health tools, telemedicine, and remote monitoring can expand reach to underserved populations and support adherence to oral or subcutaneous regimens.

Finally, companies should emphasize transparent engagement with regulators and payers early in development to align on evidentiary requirements and to design pragmatic post-approval evidence-generation plans. By combining operational resilience with clinically focused commercialization strategies, industry leaders can accelerate uptake of innovative therapies while safeguarding long-term sustainability.

Methodological framework combining expert primary research with rigorous secondary synthesis to validate clinical, regulatory, and commercial insights

This research synthesis is grounded in a mixed-methods approach that triangulates primary expert input with comprehensive secondary analysis to provide a robust, defensible perspective on liver cancer therapeutics. Primary research consisted of structured interviews and consultations with clinical thought leaders, oncology pharmacists, payer representatives, and senior commercial executives to capture real-world practice patterns, reimbursement dynamics, and strategic priorities. These expert insights were used to contextualize trends and validate themes emerging from documentary analysis.

Secondary research involved systematic review of peer-reviewed literature, regulatory guidance documents, clinical trial registries, and company disclosures to map therapeutic advances, trial outcomes, and evidence trajectories. Information from public health agencies and specialty society guidelines was synthesized to understand standard-of-care shifts and diagnostic adoption patterns. Data quality was ensured through cross-referencing of multiple independent sources and iterative validation with subject matter experts.

Limitations of the methodology include the evolving nature of clinical evidence and policy environments, which may change subsequent to the research window. To mitigate this, the approach emphasizes transparent documentation of data provenance and encourages ongoing monitoring of regulatory decisions and major clinical readouts. The methodology balances depth and breadth to support strategic decision-making while acknowledging the need for periodic updates as the field advances.

Final synthesis emphasizing the need to align scientific innovation, operational resilience, and payer-focused evidence to translate therapeutic advances into patient benefit

In conclusion, liver cancer therapeutics are being reshaped by convergent forces: scientific innovation in immuno-oncology and targeted agents, evolving care delivery and administration modalities, and external pressures such as trade policy and regional access disparities. These forces are producing new opportunities for improved patient outcomes while also introducing operational and reimbursement complexities that require coordinated responses from industry, providers, and payers. The net effect is a more dynamic, patient-centric landscape that rewards precision, flexibility, and evidence-driven commercialization.

Moving forward, stakeholders that prioritize diagnostic integration, supply chain resilience, and payer-aligned value demonstration will be better positioned to translate innovation into durable clinical and commercial success. Moreover, adaptive regulatory engagement and strategic partnerships-both clinical and commercial-will remain critical levers for accelerating patient access. Ultimately, the ability to harmonize scientific promise with pragmatic implementation will determine which therapies achieve sustained impact for the diverse populations affected by liver malignancies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Liver Cancer Drugs Market, by Therapy Type

  • 8.1. Chemotherapy
  • 8.2. Immunotherapy
  • 8.3. Radiation Therapy
  • 8.4. Targeted Therapy

9. Liver Cancer Drugs Market, by Cancer Type

  • 9.1. Cholangiocarcinoma
  • 9.2. Hepatoblastoma
  • 9.3. Hepatocellular Carcinoma (HCC)

10. Liver Cancer Drugs Market, by Administration Route

  • 10.1. Intravenous
  • 10.2. Oral
  • 10.3. Subcutaneous

11. Liver Cancer Drugs Market, by Drug Class

  • 11.1. Cytotoxic Agents
  • 11.2. Monoclonal Antibodies
  • 11.3. Tyrosine Kinase Inhibitors (TKIs)

12. Liver Cancer Drugs Market, by End User

  • 12.1. Home Care
  • 12.2. Hospital
  • 12.3. Specialty Clinic

13. Liver Cancer Drugs Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Online Pharmacy
  • 13.3. Retail Pharmacy

14. Liver Cancer Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Liver Cancer Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Liver Cancer Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Liver Cancer Drugs Market

18. China Liver Cancer Drugs Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Agenus Inc.
  • 19.6. AstraZeneca AB
  • 19.7. AstraZeneca PLC
  • 19.8. Bayer AG
  • 19.9. BeiGene, Ltd.
  • 19.10. Bristol-Myers Squibb Company
  • 19.11. Can-Fite BioPharma Ltd.
  • 19.12. Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  • 19.13. CStone Pharmaceuticals
  • 19.14. Eisai Co., Ltd.
  • 19.15. Eli Lilly and Company
  • 19.16. Exelixis, Inc.
  • 19.17. Hoffmann-La Roche Inc.
  • 19.18. Innovent Biologics, Inc.
  • 19.19. Ipsen SA
  • 19.20. Jiangsu Hengrui Medicine Co., Ltd.
  • 19.21. Merck & Co., Inc.
  • 19.22. Pfizer Inc.
  • 19.23. Roche Holding AG (F. Hoffmann-La Roche Ltd)
  • 19.24. Zai Lab Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LIVER CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL LIVER CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHOLANGIOCARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHOLANGIOCARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHOLANGIOCARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOBLASTOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOBLASTOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOBLASTOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA (HCC), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA (HCC), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA (HCC), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CYTOTOXIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CYTOTOXIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CYTOTOXIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS (TKIS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS (TKIS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS (TKIS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. GCC LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GCC LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. GCC LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. GCC LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 134. GCC LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 135. GCC LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. GCC LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. G7 LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. G7 LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. G7 LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. G7 LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 155. G7 LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 156. G7 LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. G7 LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. NATO LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. NATO LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. NATO LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. NATO LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 162. NATO LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 163. NATO LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. NATO LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)